Dr Joseph McCollom DO (@realbowtiedoc)

Pinned

D

Dr Joseph McCollom DO@realbowtiedoc · Jul 7

Humbled to share my (very first) primary authored paper: Top 10 Tips for #hpm about #survonc Deeply grateful for my writing mentor @GreggWeltyMD senior author @DrN_CancerPCP wisdom of @DrNicolasHart and colleagues, mentees and friends @doc_martin19 with editorial insight of…

realbowtiedoc's tweet image. Humbled to share my (very first) primary authored paper: Top 10 Tips for #hpm about #survonc

Deeply grateful for my writing mentor @GreggWeltyMD senior author @DrN_CancerPCP wisdom of @DrNicolasHart and colleagues, mentees and friends @doc_martin19 with editorial insight of…

17

24

89

4

17.0K

D

Dr Joseph McCollom DO@realbowtiedoc · 3 h

As #storms roll through the #Midwest ⛈️ I'm grateful for the #summer rain 🌧️on this #BowTieFriday @DrPWave @asaguirremd @mangarone23 @JMMCondor @BobMackey1 @AkSedai606 @sdbeck @DocWithBowtie @amarkelkar @DataExplorer21 @stephjantzen @zachradcliffphd @TheRealDSrini @kmody29…

realbowtiedoc's tweet image. As #storms roll through the #Midwest ⛈️ I'm grateful for the #summer rain 🌧️on this #BowTieFriday

@DrPWave
@asaguirremd
@mangarone23
@JMMCondor
@BobMackey1
@AkSedai606
@sdbeck
@DocWithBowtie
@amarkelkar
@DataExplorer21
@stephjantzen
@zachradcliffphd
@TheRealDSrini
@kmody29…

0

1

11

0

216

Dr Joseph McCollom DO Retweeted

F

Fumiko Ladd Chino, MD, FASCO@fumikochino · 14 h

A strange thing happened. I emailed myself to personally invite me to the conference that I am chairing. Excited to see me (and hopefully you!) at #ASCOQLTY25 😂

5

3

43

0

1.0K

Dr Joseph McCollom DO Retweeted

O

OncoAlert@OncoAlert · 23 h

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 18-24, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: 🫁🧬 ✅News From Industry: FLAURA2 Update #NSCLC 🫁 ✅Exercise in met #ProstateCancer ✅Surgery🆚RT☢️in Prostate…

0

10

32

1

10.0K

Dr Joseph McCollom DO Retweeted

T

The Oncologist@OncJournal · Jul 24

Drs @UGrewalMD and @TimothyJBrownMD discuss the evolving treatment of #stmcsm with new targeted agents 🎯like zolbetuximab for #HER2- but #CLDN182+ disease. They describe 4 biomarker (MSI/MMR, HER2, PD-L1, CLDN18.2) profiles that guide therapy #GIonc doi.org/10.1093/oncolo…

0

4

8

1

2.0K

D

Dr Joseph McCollom DO@realbowtiedoc · Jul 24

Checkout this piece where @TimothyJBrownMD and I try to take on the challenging task of describing zolbetuximab’s place in the advanced GEC treatment paradigm. @TheGutOncLab @GIMedOnc @Deebacca P.S. we are already thinking about how we’re going to update this algorithm to…

TThe Oncologist@OncJournal · Jul 24

Drs @UGrewalMD and @TimothyJBrownMD discuss the evolving treatment of #stmcsm with new targeted agents 🎯like zolbetuximab for #HER2- but #CLDN182+ disease. They describe 4 biomarker (MSI/MMR, HER2, PD-L1, CLDN18.2) profiles that guide therapy #GIonc doi.org/10.1093/oncolo…

0

5

20

1

2.0K

D

Dr Joseph McCollom DO@realbowtiedoc · 10 h

#PalloncCoP #PallOnc #HemeOnc # SuppOnc @realbowtiedoc @CThompson @Danafa

CChadane Thompson, MD@CThompson_MD · Jul 23

Very insightful didactics today @DanaFarber focused on the intersection of palliative care and oncology. The opportunity to be taught and mentored by the innovative leaders who curated these guidelines is such an honor. Time to dive into these resources! #HemOnc #PallOnc #SuppOnc

0

2

5

0

252

Dr Joseph McCollom DO Retweeted

O

OncoAlert@OncoAlert · Jul 24

Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER) buff.ly/UrXfLEu In this open-label, phase II trial of pretreated HER2-positive advanced #BreastCancer , trastuzumab plus…

2

13

29

2

2.0K

Dr Joseph McCollom DO Retweeted

C

Conquer Cancer, the ASCO Foundation@ConquerCancerFd · Jul 23

In this #YourStories episode, Dr. Eric Singhi (@LungOncDoc) discusses his mission to drown out #cancermisinformation with accurate, compelling knowledge, one post at a time. Listen now: brnw.ch/21wUnhi

0

4

10

0

640

Dr Joseph McCollom DO Retweeted

A

ACS Journal Cancer@JournalCancer · Jul 23

🚨 Big news for stomach cancer care: FDA approves adding pembrolizumab to trastuzumab and standard chemotherapy for patients with HER2+ advanced gastric/gastroesophageal junction adenocarcinoma. The full story is available in #CancerScope: 🔗 acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert

0

11

14

2

1.0K

Dr Joseph McCollom DO Retweeted

N

Nicholas Hornstein@GIMedOnc · Jul 23

💥New paper out! We reanalyzed raw sequencing data from 18,558 standard-of-care Guardant360 ctDNA assays in advanced #colorectalcancer using a partner-agnostic fusion caller. 🧬 Fusions in 1.3% of patients 🧪 93% were subclonal — enriched after EGFR therapy 🔗 Clonal fusions…

0

15

31

6

3.0K

Dr Joseph McCollom DO Retweeted

E

Emre Yekedüz@yekeduz_emre · Jul 24

🚨A must-read review in @NatRevClinOncol ➡️EMT and cancer: what clinicians should know 🎯Cancer cell plasticity fuels metastasis & treatment resistance. @OncoAlert @DrYukselUrun #cancer #Oncology #MedX 👉doi.org/10.1038/s41571…

1

18

38

13

3.0K

Dr Joseph McCollom DO Retweeted

R

Rami Manochakian MD, FASCO Cancer Education@RManochakian · Jul 23

🚨🔥Hot off the press. Just published @JCO_ASCO @ASCO Important paper on an important topic: ✅The use of Patient-Centered #Language in the Dissemination of #CancerResearch. 📝By an amazing #Scientist & #Patient-Partnered Working Group. 👇🏻 brnw.ch/21wUmvH

4

12

40

3

3.0K

Dr Joseph McCollom DO Retweeted

F

Fumiko Ladd Chino, MD, FASCO@fumikochino · Jul 23

In this analysis of >8k patients with #GIcancers: 👉45% (n=3,764) had a COST score of <26, indicating #financialToxicity 👉28% (n=2,321) reported at least 1 health related social risk... including > 1️⃣in🔟 who couldn't afford 🍔🥗, 🛏️🏡, or 🚗🚐 ascopubs.org/doi/pdfdirect/…

1

13

27

3

2.0K

Dr Joseph McCollom DO Retweeted

G

Georgia Cancer Center@GACancerCenter · Jul 10

Last week, @asfeen_ummul was presented with a certificate by @GCC_Cortes to show our appreciation for her work at our Hereditary Cancer Clinic. Asfeen is now pursuing a fellowship at MD Anderson Cancer Center in Houston. We wish you all the best!

1

4

24

0

2.0K

Dr Joseph McCollom DO Retweeted

C

Chadane Thompson, MD@CThompson_MD · Jul 23

Very insightful didactics today @DanaFarber focused on the intersection of palliative care and oncology. The opportunity to be taught and mentored by the innovative leaders who curated these guidelines is such an honor. Time to dive into these resources! #HemOnc #PallOnc #SuppOnc

0

4

19

0

1.0K

Dr Joseph McCollom DO Retweeted

R

Ryan Nipp, MD, MPH, MBA, FASCO@RyanNipp · Jul 23

Frequent Missed Opportunities for Earlier Diagnosis of Advanced-Stage Colorectal or Lung #Cancer. jamanetwork.com/journals/jamai… @JAMA_current @JAMANetwork @JAMAInternalMed #ColonCancer #LungCancer #CancerResearch #CancerScreening

1

4

13

2

1.0K

Dr Joseph McCollom DO Retweeted

A

Advanced Prostate Cancer Consensus Conference@APCCC_Lugano · Jul 23

Exercise in patients with metastatic prostate cancer: A comprehensive review cancertreatmentreviews.com/article/S0305-… Physical activity🏃 and structured exercise have been shown to significantly improve quality of life in #ProstateCancer (PC) patients, particularly by alleviating side effects…

1

17

28

7

2.0K

D

Dr Joseph McCollom DO@realbowtiedoc · Jul 23

Congratulations @JordanCurry2 & colleagues! @PallOncCoP

JJordan Curry, PhD@JordanCurry2 · Jul 23

Thrilled to see our paper getting shared! It was a privilege to present it pre-pub at @CancerCareMASCC Grateful for the guidance of incredible mentors @cindycforbes & @C_Caperchione, & for thoughtful peer review from the @MASCC_JSCC team @MJJohnson_HYMS @HullYorkMed @UTSEngage

0

2

3

0

204

D

Dr Joseph McCollom DO@realbowtiedoc · Jul 23

Thrilled to see our paper getting shared! It was a privilege to present it pre-pub at @CancerCareMASCC Grateful for the guidance of incredible mentors @cindycforbes & @C_Caperchione, & for thoughtful peer review from the @MASCC_JSCC team @MJJohnson_HYMS @HullYorkMed @UTSEngage

MMASCC@CancerCareMASCC · Jul 21

A new open access systematic review in @MASCC_JSCC evaluates the feasibility, acceptability, and efficacy of digital technology to deliver physical activity and nutrition interventions for adults with advanced or incurable cancer. Read more: link.springer.com/article/10.100…

0

6

21

1

1.0K